Print

Active Biotech Interim report January - June 2005

2005-08-11

  • All projects progressing in accordance with planned milestones

  • Issue totaling approximately SEK 169 M completed - oversubscribed by 43 percent
  • Exercise of option to repurchase research facility in Lund
  • Net sales: SEK 5.8 M (30.4)
  • Operating loss: SEK 100.5 M (loss: 97.0)
  • Loss after tax: SEK 110.3 M (loss: 76.6)
  • Loss per share for the period: SEK 3.27 (loss: 2.27)

  • pdfActive Biotech Interim report Jan-Jun 05



    Back